These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

73 related articles for article (PubMed ID: 20427634)

  • 1. Negotiating treatment for hepatitis C: interpersonal alignment in the clinical encounter.
    Körner H
    Health (London); 2010 May; 14(3):272-91. PubMed ID: 20427634
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The drugs that dare not speak their name: Injecting and other illicit drug use during treatment for hepatitis C infection.
    Hopwood M; Treloar C
    Int J Drug Policy; 2007 Oct; 18(5):374-80. PubMed ID: 17854725
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The experience of interferon-based treatments for hepatitis C infection.
    Hopwood M; Treloar C
    Qual Health Res; 2005 May; 15(5):635-46. PubMed ID: 15802540
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The analysis of physicians' work: announcing the end of attempts at in vitro fertilization].
    Santiago-Delefosse M; Cahen F; Coeffin-Driol C
    Encephale; 2003; 29(4 Pt 1):293-305. PubMed ID: 14615699
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patients' values for health states associated with hepatitis C and physicians' estimates of those values.
    Cotler SJ; Patil R; McNutt RA; Speroff T; Banaad-Omiotek G; Ganger DR; Rosenblate H; Kaur S; Cotler S; Jensen DM
    Am J Gastroenterol; 2001 Sep; 96(9):2730-6. PubMed ID: 11569703
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patients' experiences related to anti-viral treatment for hepatitis C.
    Fraenkel L; McGraw S; Wongcharatrawee S; Garcia-Tsao G
    Patient Educ Couns; 2006 Jul; 62(1):148-55. PubMed ID: 16098705
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Receiving a hepatitis C-positive diagnosis.
    Hopwood M; Treloar C
    Intern Med J; 2004; 34(9-10):526-31. PubMed ID: 15482264
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Living with hepatitis C and treatment: the personal experiences of patients.
    Sgorbini M; O'Brien L; Jackson D
    J Clin Nurs; 2009 Aug; 18(16):2282-91. PubMed ID: 19583661
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatitis C important treatment advance: interview with Douglas Dieterich, M.D. Interview by John S. James.
    Dieterich D
    AIDS Treat News; 1998 May; (No 295):1-5. PubMed ID: 11365406
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Limited effectiveness of antiviral treatment for hepatitis C in an urban HIV clinic.
    Mehta SH; Lucas GM; Mirel LB; Torbenson M; Higgins Y; Moore RD; Thomas DL; Sulkowski MS
    AIDS; 2006 Nov; 20(18):2361-9. PubMed ID: 17117023
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Physicians' communication with patients about adherence to HIV medication in San Francisco and Copenhagen: a qualitative study using Grounded Theory.
    Barfod TS; Hecht FM; Rubow C; Gerstoft J
    BMC Health Serv Res; 2006 Dec; 6():154. PubMed ID: 17144910
    [TBL] [Abstract][Full Text] [Related]  

  • 12. How physicians describe outcomes to HCV therapy: prevalence and meaning of "cure" during provider-patient in-office discussions of HCV.
    Hamilton HE; Gordon C; Nelson M; Cotler SJ; Martin P
    J Clin Gastroenterol; 2008 Apr; 42(4):419-24. PubMed ID: 18277894
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HIV/hepatitis coinfection in eastern Europe and new pan-European approaches to hepatitis prevention and management.
    Lazarus JV; Shete PB; Eramova I; Merkinaite S; Matic S
    Int J Drug Policy; 2007 Oct; 18(5):426-32. PubMed ID: 17854732
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Everybody's got it, but...: situational and strategic participation in normalized HCV discourse among injection drug users in Edmonton, Canada.
    Wozniak L; Prakash M; Taylor M; Wild TC
    Int J Drug Policy; 2007 Oct; 18(5):388-96. PubMed ID: 17854727
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pretreatment preparation and management of interferon-based therapy for hepatitis C virus infection.
    Hopwood M; Treloar C
    J Adv Nurs; 2007 Aug; 59(3):248-54. PubMed ID: 17524045
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Circulating beliefs, resilient metaphors and faith in biomedicine: hepatitis C patients and interferon combination therapy.
    Jenner A; Scott A
    Sociol Health Illn; 2008 Mar; 30(2):197-216. PubMed ID: 18290932
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Provider-patient in-office discussions of response to hepatitis C antiviral therapy and impact on patient comprehension.
    Hamilton HE; Nelson M; Martin P; Cotler SJ
    Clin Gastroenterol Hepatol; 2006 Apr; 4(4):507-13. PubMed ID: 16616357
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hazardous alcohol consumption and other barriers to antiviral treatment among hepatitis C positive people receiving opioid maintenance treatment.
    Watson B; Conigrave KM; Wallace C; Whitfield JB; Wurst F; Haber PS
    Drug Alcohol Rev; 2007 May; 26(3):231-9. PubMed ID: 17454012
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The decision to forgo antiretroviral therapy in people living with HIV compliance as paternalism or partnership?
    Kremer H; Bader A; O'Cleirigh C; Bierhoff HW; Brockmeyer NH
    Eur J Med Res; 2004 Feb; 9(2):61-70. PubMed ID: 15090291
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [In chronic hepatitis C, delays between diagnosis and treatment are linked to the doctor-patient relationship].
    Enel C; Minello A; Jooste V; Pinoit JM; Hillon P
    Med Sci (Paris); 2009 May; 25(5):519-23. PubMed ID: 19480834
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.